Thalassemia

Thalassemia is a group of inherited hemoglobinopathies characterized by reduced synthesis of one or more globin chains, resulting in chronic hemolytic anemia and ineffective erythropoiesis. The disease is caused by point mutations, deletions, or insertions in genes encoding α or β globin chains, leading to imbalanced globin chain production. With an estimated 330 million carriers worldwide and highest prevalence in Mediterranean, Middle Eastern, African, and Southeast Asian populations, thalassemia represents a major global health burden. Clinical severity ranges from asymptomatic trait forms to transfusion-dependent life-threatening disease, making accurate classification essential for prognostic counseling and management planning. Thalassemia is a high-yield topic for USMLE Step 2 CK given its integration of genetics, hemolysis pathophysiology, and chronic disease management principles. Understanding the spectrum from thalassemia minor (trait) through thalassemia intermedia to thalassemia major is critical for board preparation.

The fundamental defect in β-thalassemia major involves severely reduced or absent β-globin chain synthesis, typically from homozygous β-globin gene mutations. Normal adult hemoglobin (HbA) consists of two α and two β globin chains (α₂β₂). When β-chain production falls below ~30% of normal, unpaired α-globin chains accumulate and precipitate as Heinz bodies within erythroid precursors. These precipitates are toxic to cell membranes, triggering apoptosis of erythroid progenitors (ineffective erythropoiesis) and premature destruction of circulating red blood cells (hemolytic anemia). The combination of decreased RBC production and accelerated RBC destruction creates severe anemia, typically manifesting within the first 6-12 months of life as fetal hemoglobin (HbF) production wanes and HbA becomes the predominant hemoglobin form.

The body responds to profound anemia with massive compensatory erythroid hyperplasia driven by elevated erythropoietin (EPO). This erythroid proliferation expands the bone marrow cavity, causing skeletal deformities (frontal bossing, maxillary prominence, orbital expansion) and pathologic fractures from osteoporosis. Additionally, patients require chronic red blood cell transfusions (10-20 units annually) to maintain hemoglobin levels for tissue oxygenation and suppress ineffective erythropoiesis. Each unit of transfused blood delivers approximately 250 mg of iron; since the body lacks a physiologic iron excretion mechanism, iron accumulates in the myocardium, liver, pituitary, and endocrine organs causing secondary hemochromatosis. Iron-catalyzed free radical formation through Fenton chemistry generates oxidative damage leading to restrictive cardiomyopathy, cirrhosis, endocrine insufficiency, and early death in untreated patients.

Thalassemia intermedia results from mutations allowing 30-80% of normal β-globin synthesis or from less severe genotypes (e.g., homozygous β⁰ thalassemia with coinheritance of α-globin gene deletion or hereditary persistence of fetal hemoglobin). Patients maintain hemoglobin levels of 7-10 g/dL without regular transfusions, though splenomegaly from extramedullary hematopoiesis causes mass effect and splenic sequestration of RBCs. The reduced transfusion burden (0-5 units/year) decreases iron overload risk, but residual hemolysis and ineffective erythropoiesis still drive complications including gallstones, leg ulcers, thromboembolism (from endothelial activation), and splenectomy-related complications.

Heterozygous carriers of one β-globin mutation produce 50-80% of normal β-globin from the normal allele, with RBC indices showing mild microcytosis (MCV 60-75 fL) and slightly elevated red cell distribution width (RDW). The degree of chain imbalance is insufficient to cause significant hemolysis or anemia (hemoglobin typically 11-13 g/dL in females, 12-14 g/dL in males). RBC morphology shows target cells (codocytes) and hypochromia from reduced mean corpuscular hemoglobin (MCH < 27 pg). Patients are clinically asymptomatic but risk inheritance of severe disease if partner carries a thalassemia mutation.

α-thalassemia differs mechanistically because four functional α-globin genes exist (two on each chromosome 16), allowing deletion of 1-4 genes:

Over 200 distinct mutations affecting the β-globin gene have been identified, classified as β⁰ (no β-globin production) or β⁺ (reduced production). Common mutations include promoter region alterations (e.g., TATA box mutations), splice site mutations, and point mutations creating premature stop codons. β⁰/β⁰ genotypes or β⁰/β⁺ genotypes with severe β⁺ mutations cause thalassemia major, while β⁺/β⁺ or β⁺/β- with mild mutations typically produce intermedia phenotypes. Geographic variation is pronounced: Mediterranean populations carry high frequencies of Mediterranean-type mutations, African populations carry different allelic variants, and Southeast Asian populations predominate with E-β⁰ combinations.

The severity of β-thalassemia depends not only on the primary β-globin mutation but on genetic modifiers that influence final phenotype. Hereditary Persistence of Fetal Hemoglobin (HPFH) arises from mutations in γ-globin regulatory regions or coinheritance of specific C/T polymorphisms in the BCL11A locus, allowing continued fetal hemoglobin (HbF) production into adulthood. Patients with β-thalassemia who coinherit HPFH have dramatically improved outcomes because HbF (~70-80% of total hemoglobin) compensates for absent β chains, reducing hemolysis and transfusion requirements. Conversely, coinheritance of α-thalassemia trait (common in Asian and African populations) paradoxically worsens β-thalassemia major by further imbalancing globin chains and increasing precipitated α chains.

α-thalassemia arises from deletions of one or more of four α-globin genes clustered on chromosome 16. The Southeast Asian (-SEA) and Mediterranean (--MED) deletions remove both genes on one chromosome (cis deletions), whereas the α² and α¹ deletions remove single genes (trans deletions). Population genetics determine inheritance patterns: Southeast Asian and African populations show predominantly cis deletions with risk of severe disease (hydrops fetalis), while Mediterranean and African populations carry heterogeneous patterns. Nondeletion α-thalassemia (from point mutations affecting α-globin chain termination or processing) accounts for ~15-20% of cases, typically causing milder phenotypes.

Geographic origin strongly predicts thalassemia genotype and phenotype. β-Thalassemia major predominates in Mediterranean, North African, and Middle Eastern populations; HbE-β⁰ thalassemia is most common in Southeast Asia; and various forms occur throughout sub-Saharan Africa and South Asia. Consanguinity increases risk in endemic areas by increasing homozygosity rates.

Affected neonates are typically born healthy because fetal hemoglobin (α₂γ₂) synthesis remains intact in utero. As HbF production normally declines 3-6 months postnatally and HbA (α₂β₂) should become predominant, patients with absent or severely deficient β-globin chains develop progressive anemia. Presentation typically occurs at 6-12 months with failure to thrive, developmental delay, irritability, and reduced activity level. Parents frequently report feeding difficulties, decreased playfulness, and pallor that worsens over weeks to months. Hepatosplenomegaly develops as extramedullary hematopoiesis (blood-forming tissue outside the marrow) compensates for bone marrow failure and splenic sequestration increases. Jaundice may appear transiently if hemolysis is brisk.

Untreated patients develop severe microcytic anemia (hemoglobin 6-8 g/dL or lower) with profound tissue hypoxia. High-output cardiac failure develops insidiously from chronic anemia forcing increased cardiac output (cardiac output = hemoglobin × oxygen saturation × heart rate); over years, chronic volume overload causes eccentric left ventricular hypertrophy, mitral regurgitation, and eventually systolic dysfunction. Patients experience dyspnea, exercise intolerance, and lower extremity edema. The severely microcytic RBCs increase whole blood viscosity, increasing risk of splenic infarction and thromboembolism.

Massive expansion of the bone marrow cavity causes frontal bossing (prominent forehead from diploe expansion), maxillary prominence (protruding upper jaw), orbital expansion (widened eye orbits), and general facial deformity described as "chipmunk facies." The expanded marrow crowds out normal bone architecture, causing osteoporosis with pathologic fractures, vertebral collapse, and kyphoscoliosis. The axial skeleton is more severely involved than appendicular bones. Growth stunting results from nutritional demands of erythropoiesis, iron overload toxicity, and endocrine dysfunction.

Chronic transfusions (and increased GI iron absorption from ineffective erythropoiesis) cause iron accumulation in myocardium, liver, pituitary, pancreas, and parathyroid glands. Iron generates free radicals via Fenton chemistry (Fe²⁺ + H₂O₂ → Fe³⁺ + OH⁻ + OH•), causing oxidative damage to cell membranes and organelles.

Chronic hemolysis produces unconjugated hyperbilirubinemia, promoting cholesterol and pigment gallstone formation. Biliary colic and acute cholecystitis occur. Splenectomy increases thrombotic risk and infections.

Patients typically present later in childhood (1-3 years) with mild-to-moderate anemia, splenomegaly, and rarely hepatomegaly. Growth delay may be mild. Splenectomy-related complications (overwhelming sepsis from encapsulated organisms, thromboembolism) represent major morbidity sources. Leg ulcers over the lateral malleoli develop in 2-5% from chronic hemolysis, ineffective erythropoiesis, and local stasis. Thromboembolism (stroke, myocardial infarction, pulmonary embolism) occurs at higher rates than general population, likely from platelet activation, endothelial dysfunction, and increased blood viscosity.

Patients are asymptomatic with only microcytic, hypochromic anemia detected on screening labs or during investigation for microcytic anemia in another context. Hemoglobin is typically >11 g/dL, allowing normal daily activities. Rarely, patients with thalassemia trait may experience mild symptoms with physiologic stress (pregnancy, infection, hypoxia).

Diagnosis should be suspected in any child presenting with microcytic, hypochromic anemia, particularly from endemic populations or with positive family history. The key distinction is between iron deficiency anemia (most common cause of microcytic anemia) and thalassemia trait/disease. Peripheral blood smear findings suggestive of thalassemia include target cells, nucleated RBCs (in major disease), and Heinz bodies (in HbH disease and severe major).